Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer

Maja Lynge RasmussenDepartment of Oncology, Aarhus University Hospital, Aarhus, DenmarkCorrespondence[email protected]

Gabor LipositsDepartment of Oncology, Herning Hospital, Denmark

Subethini YogendramDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark

Anders Bonde JensenDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark

Søren LinnetDepartment of Oncology, Herning Hospital, Denmark

Sven Tyge LangkjerDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark

References

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;12:69–90.
Web of Science ®Google Scholar
Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008;100:1179–83.
PubMedGoogle Scholar
Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE); a phase 3 open-label randomised study. Lancet 2011;377:914–23.
PubMed Web of Science ®Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date